Fujian Shengdi Pharmaceutical Co., Ltd. Drug Pipeline

Fujian Shengdi Pharmaceutical Co., Ltd. maintains a substantial portfolio of clinical trials, with 47 trials registered since 2008, including 25 currently active programs. These active trials span multiple phases of development: 7 in Phase 1, 11 in Phase 2, and 7 in Phase 3. The company's research is focused across five therapeutic areas, with a significant concentration in metabolic disorders. Within the metabolic area, Fujian Shengdi has 12 active trials, representing 48% of its active portfolio. Key indications within metabolic disorders include obesity (6 active trials, 3 in Phase 3) and Type 2 diabetes (4 active trials, 3 in Phase 3). The remaining active trials are distributed across cardiovascular diseases (5 active trials), infectious diseases (2 active trials), and women's health (1 active trial). The relatively high number of Phase 3 trials in obesity and Type 2 diabetes suggests a potential for near-term clinical catalysts in these indications.